(NASDAQ: EYPT) Eyepoint's forecast annual revenue growth rate of 349.18% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.45%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Eyepoint's revenue in 2026 is $2,579,000.On average, 15 Wall Street analysts forecast EYPT's revenue for 2026 to be $198,550,632, with the lowest EYPT revenue forecast at $111,506,945, and the highest EYPT revenue forecast at $322,573,662. On average, 15 Wall Street analysts forecast EYPT's revenue for 2027 to be $531,819,858, with the lowest EYPT revenue forecast at $0, and the highest EYPT revenue forecast at $5,435,963,572.
In 2028, EYPT is forecast to generate $33,027,674,431 in revenue, with the lowest revenue forecast at $1,561,097,231 and the highest revenue forecast at $105,230,697,009.